340B Health

340B Insight Podcast

340B Insight

340B Insight is 340B Health’s podcast, providing our members and supporters with timely news updates and discussion around the 340B drug pricing program. The podcast enables listeners to stay current and expand their knowledge of 340B to help them serve their patients and communities and remain compliant with rules and requirements. New episodes are published twice per month and include news update segments and in-depth interviews with leading experts including health care practitioners, policy and legal experts, public policymakers, and our expert staff.

Listen and Subscribe

Have a question or suggestion for 340B Insight? Email us at: podcast@340bhealth.org

Podcast sponsorship opportunities are available. Email to learn more: robin.hayes@340bhealth.org

Follow 340B Health on Twitter, Facebook, and LinkedIn

 


Episodes

  • Episode 86: Major New Developments End an Exciting Year for 340B

    The past several months have seen several major developments in the world of 340B drug pricing. 340B Health President and CEO Maureen Testoni returns to the show to break down some of the most important recent 340B stories. (Transcript)

    Read more

  • Episode 85: How To Engage Your Leadership on 340B

    In July, Karen Bowling became the new chair of the 340B Health Board of Directors. The West Virginia native is the president and CEO of Princeton Community Hospital and executive vice president of government affairs for West Virginia University Health System (WVU Medicine).

    In this episode, Bowling discusses her clinical and leadership experience, her 340B advocacy and communications work, and her advice for getting hospital and health system leaders engaged on 340B. (Transcript)

    Read more

  • Episode 84: 340B in the States: 2023 State Legislative Recap and 2024 Outlook

    This week we are joined by Amanda Sellers Smith, legal counsel for 340B Health. Amanda tracks and responds to 340B state legislative and regulatory actions. She discusses recent developments in state-based legislation, including 340B reporting requirements, nondiscrimination prohibitions, and bans on drugmaker restrictions. She also looks ahead to what hospitals and their government relations departments can expect in 2024. Before the interview, we give an update on a set of unprecedented changes to a major drugmaker’s restrictive contact pharmacy policy, and we share the news that four of the five drugmakers that HRSA audited last fiscal year for 340B compliance received findings for overcharging covered entities. (Transcript)

    Read more

  • Episode 83: How Centralized Distribution Affects Health Care

    Centralized distribution models can help health systems streamline day-to-day operations, including mitigating drug shortages, and maximizing contract compliance and efficiency. Jake Olson, 340B pharmacy manager at Froedtert Memorial Lutheran Hospital in Milwaukee, Wisconsin, joins us to discuss how centralized distribution models have operationalized Froedtert’s 340B program. (Transcript)

    Read more

  • Episode 82: 340B Legislative and Regulatory Update from Maureen Testoni

    Several key developments in 340B-related legislation and regulation have occurred in recent weeks, and more are expected this fall. In this episode, Maureen Testoni returns to the show to give her updates on where 340B stands in Congress, in state legislatures, and with the administration. (Transcript)

    Read more

  • Episode 81: The Power of 340B Crosswalks

    340B compliance is essential to the integrity and success of the program, and data management across hospital departments is an essential element of compliance. By implementing data crosswalks, 340B hospitals can achieve greater program compliance and optimization. Anja Wilkinson, 340B program manager at St. Francis Health System in Tulsa, Okla., joins us to speak about best practices for 340B crosswalks and how interdepartmental coordination is key to maximizing the benefits of 340B.

    Before the interview, we give an update on the projected effects on the 340B program of the first 10 Medicare Part D drugs subject to caps starting in 2026 under the Inflation Reduction Act and the negative effects of the Stop Drug Shortages Act if it is passed into law as currently drafted. (Transcript)

    Read more